ReviewEpigenetics & chromatin2026
Epigenetic deciphering of ovarian aging: multilayer interactive mechanisms and targeted reversal strategies.
Review in Epigenetics & chromatin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ovarian aging leads to the progressive loss of reproductive and endocrine functions. As an upstream regulatory hub, epigenetic modifications synergistically impair these two functions through multi-dimensional mechanisms, collectively contributing to the occurrence of clinical phenotypes. Current therapies (e.g., hormone replacement therapy) are difficult to reverse functional decline and carry long-term risks. This review systematically elaborates on the core roles of three major epigenetic mechanisms in ovarian aging: DNA methylation (mediated by DNMTs/TET), histone modification (dynamic balance of HATs/HDACs), and non-coding RNA (miRNA/lncRNA/circRNA network). Dysregulation of DNA methylation reprogramming drives the imbalance between dormancy and activation of primordial follicles and impairs steroidogenesis. Dysregulated histone modification induces spindle assembly defects, meiotic arrest, and a vicious cycle of apoptosis and autophagy in granulosa cells. ncRNAs regulate oocyte maturation through the ceRNA mechanism and epitranscriptomic reprogramming (e.g., m6A). These mechanisms synergistically accelerate ovarian aging through multiple pathways, including interfering with the HPG axis, aggravating oxidative stress-mitochondrial dysfunction, and disrupting apoptosis/autophagy homeostasis. Although epigenetic interventions still face potential transgenerational genetic safety risks, against the backdrop of high incidence and global population aging, the development of novel therapies that specifically target somatic cells or can avoid such risks has become an urgent need. In the future, targeting key epigenetic nodes is still expected to open up new avenues for extending female reproductive lifespan and alleviating long-term health risks associated with ovarian aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.